Veterinary & One Health
MARCH 30 - APRIL 2, 2026
WALTER E. WASHINGTON CONVENTION CENTER, WASHINGTON D.C.
Washington D.C., 30 March 2026 - 2 April 2026
Schedule
Create your personal agenda –check the favourite icon
BIODEFENSE & BIOSECURITY WORKSHOP
- :00 – 10:05 Opening RemarksWorkshop Chair: Taylor Sexton, Executive Director, Medical Countermeasures Coalition
- Understanding USG’s R&D, regulatory and policy priorities.ASPR Leadership TBC
10:25 – 11.15am Securing the Nation: Aligning U.S. Strategic Priorities, Investment, and Technology in Biodefense
- Strategic Priorities: Outlining the specific threats (e.g., emerging pathogens, select agents, or novel delivery systems) that are driving current policy and planning.
- Investment Areas: Identifying critical funding priorities for the next generation of medical countermeasures, platform technologies, and supply chain resilience.
- Technological Frontiers: Discussing promising new technologies, such as on-demand manufacturing, continuous fermentation for therapeutics, and advanced modeling/diagnostics, that are essential to achieving rapid response capabilities.
11.15 – 12pm Panel: Redefining Preclinical Development: Non-clinical models to support development and licensure
- NIH funding shifts
- Transition from animal models
- Organ-on-a-Chip, In Silico Models & Regulatory Pathways
- Integration of new models into FDA submissions
- Implications for accelerated approval
2pm Afternoon chair’s opening remarks:
2:05 – 2.30pm Promoting Standardization of International Protocols for Biosecurity
2:30 – 2:50pm Ensuring Assay Integrity: The Role of Authenticated Reference Data in Biodefense
2:50 – 3:10pm Presentation TBC
3:10- 4:10pm Panel: Biosecurity & Bots: Setting the Guardrails for AI in Vaccine R&D
- Identifying and mitigating the risks of AI "hallucination" and erroneous data in vaccine research and development.
- Establishing oversight and accountability to safeguard AI tools, especially concerning drug safety and efficacy.
- The need for "AI police" or quality assurance to check code and validate AI outputs before they impact clinical trials.
- Discussing the challenge of moving away from manual expertise and the potential loss of human validation in pharmacovigilance and research.
- Examining the biosecurity implications of unregulated AI tools in creating novel molecules and designing preclinical models for vaccines.
- Forecasting Future Biothreats: Integrating AI and Global Surveillance.
- Exploring predictive analytics, AI-driven bio-surveillance, and early warning systems.
4:10pm – 5:00pm Panel: Lessons from Regional Biodefense Hubs (Africa, SoutheastAsia, Latin America + others)
- How regional biodefense hubs are transforming public health preparedness through innovation, collaboration, and capacity building.
- Case studies on:
- Building genomic surveillance and laboratory capacity
- Deploying One Health strategies to monitor zoonotic threats
- Strengthening regional regulatory and manufacturing ecosystems
- Leveraging AI, wastewater surveillance, and climate modeling for early detection
- Creating sustainable funding and equitable partnerships
10:05– 10:25 Priorities For R&D And Funding of Medical Countermeasures for Biodefense and Biosecurity
Antimicrobial Resistance Workshop
Workshop Chair: Dr Christian Harding, CSO and Co-Founder, Omniose
- 10.00 Chair’s Opening Remarks
- 10:10 Keynote Intro – Impact of Vaccines on AMR *Topic TBC
- 10.30 Advancing Immunity: Clinical Development of a Peptide Conjugate Vaccine for Group A Streptococcus
- 10.45 Leveraging Serological Insights to Combat Emerging Pathogens and Antimicrobial Resistance
- 11.00 Selecting the Right Platform to Combat AMR
- 11.15 Creative Approaches to Licensure
- 11.30 De-risking Early Vaccine Development: Insights from CHIM, NHP Studies, and Correlates of Protection
- 11.45 Combining approaches to Maximize Impact: P. aeruginosa Vaccine
- 12:00 Mitigating AMR in LMICs: The Role of Vaccines in a One Health World
- 12.15 Panel Discussion: Perceptions of AMR Vaccine Development in the Current Global Climate
- 14:00 – 15:00 Funding Pipeline Updates
- 14:00 Gates Foundation
- 14:15 CARB-X
- 14:30 BactiVac
- 14:45 Wellcome Trust
- 15:00- 16:00 AMR Vaccines Development Updates
- 15:00 Shigella / Acinetobacter Vaccine Development *Title TBC
- 15:15Universal Pneumococcal Vaccine Development *Title TBC
- Dr Tim Hirst, Chairman & CEO, GPN Vaccines
- 15:30Stopping Superbugs: The Future of Anti-Bacterial Vaccine Development *Title TBC
- 15:45 Advancing a multivalent vaccine candidate to prevent S.aureus skin infections
- 16:00 Panel: Are Combination Vaccines the Way Forward for AMR /Defining the Value of Combo Vaccines?
- Economic valuation of vaccines with reduction on AMR
- Improving coverage of viral vaccines which reduce AMR
- Explore the concept of Syndromic vaccines
ANTIBODIES FOR INFECTIOUS DISEASES WORKSHOP
- rkshop Chair: Dr Mark T. Esser, Chief Scientific Officer & Head, Paul and Diane Manning Institute of Biotechnology
- Development of mAbs for infectious diseases
- mAb design
- Reducing the cost of mAb manufacturing
10.10am – 12:00pm Development of mAbs for ID
10.10am Next-Generation HIV mAbs: Optimizing Potency, Duration, and Global Access *Title TBCDr Jon Heinrichs, Vice President & Head of Discovery Science, IAVI
10:30am Novel DNA-Encoded Monoclonal Antibody Technology: Durable and Tolerable In Vivo Expression of mAbs Targeting COVIDDr Laurent Humeau, CSO, Inovio
10:50am Developing mAb therapies that keep pace with rapidly evolving viral threatsDr Robert Allen, CSO, Invivyd
11.10am From Bench to Broad Access: The journey of nirsevimab, a long-acting mAb against RSVSenior Representative, Sanofi *TBC
11:30am The Sepsis Antibody Breakthrough: restoring immune function with hCitH3-mAbDr Jianjie Ma, Professor, Surgery, University of Virginia
11.50am Targeting the recurrence epidemic: the development and promise of AZD5148, an anti-toxin B monoclonal antibodyAstraZeneca – Invited
12:10pm Development of unique tetravalent antibodies for COVID and Flu *Title TBCDr John Mascola, CSO, Modex Therapeutics
12:30pm mAbs for S.aureusGSK - invited
1pm - 2pm Netowrking Break
2pm Presentation TBC
2:20pm – 3:20pm Panel: Next-Gen mAb Manufacturing: Beyond CHO & Protein A *Title TBC
- Process Intensification: Adopting continuous bioprocessing (perfusion) to reduce facility CapEx and achieve savings.
- Downstream Disruption: Replacing expensive Protein A chromatography with alternative, high-throughput purification platforms.
- Digital Biomanufacturing: Leveraging Machine Learning and PAT for real-time process optimization and consistent product quality.
- Novel Expression Systems: Utilizing non-mammalian hosts (e.g., fungi/C1) and in vivo technologies like DMAbs for radical cost reduction.
- The $10/g Goal: Discussing the technical and regulatory pathways required to make mAbs globally accessible.
Multi-specific Antibodies and Cocktails: The Future of Complex ID Intervention
- The technical hurdles of discovering, engineering, co-manufacturing and co-formulating multiple mAbs or multi-specific formats.
- Designing mAbs that target multiple mechanisms (e.g., neutralizing toxin and facilitating pathogen clearance).
- Clinical trial design challenges for combination products in infectious disease settings.
- Regulatory challengesAZ / Modex
Topics
Vaccine Technology Workshop
Topics:
· Cutting-edge technologies shaping the future of vaccine development.
· Adjuvants
· AI tools for Protein Design/Epitopes
Worlshop Chair: Dr David Burkhart, Chief Executive Officer, Inimmune
- 10am Chair’s Opening Remarks
- 10.10am Self-replicating RNA Platform Development
- 10.25am Designing the Next Generation of Vaccines: Harnessing Generative AI for In Silico Immunogen Discovery
- 10.40 Virus-Like Particle Display for Long-Lasting Vaccine Protection
- Senior Representative, AdaptVac
- 10:55 Reserved
- 11:10 Reserved
- 11:25 Reserved
- 11:40Engineering Modular Immunogen Platforms to Neutralize Evolving Chemical Threats *Title TBC
- 12:00 Panel: The Evolving Landscape of Novel Adjuvant Development – Navigating Safety, Access and Innovation
- Safety as a priority and hurdle for the acceptance novel adjuvants
- How can we further de-risk adjuvants?
- Changing Models in licensing and access, how will non-exclusive licensing change the field?
- Can innovation and adoption of new technologies overcome barriers in cost and access?
CHRONIC DISEASE, AUTOIMMUNITY & THE VIROME WORKSHOP (AM)
Exploring the drivers and development of vaccines against non-infectious disease targets
- Virome Discovery: Mapping the Invisible Drivers of Disease
- Uncovering the Immune Landscape of Autoimmune Disease: From Parkinsons to ALS
- Vaccines for autoimmunity
- The shingles vaccine and dementia: A causal relationship?
Panel: Adjuvants and Immunity: Exploring Systemic Benefits Beyond Zoster
- - Beyond Shingles: Explore emerging data linking zoster vaccines to reduced risks of cardiovascular disease and Alzheimer’s.
- - Immunological Insights: Discuss how zoster vaccines adjuvant systems may drive systemic immune benefits beyond zoster prevention
- - Correlates of Protection: Identify immune markers that may explain long-term protection and -potential cross-disease benefits.
- - Public Health Implications: Debate whether zoster vaccines should be recommended earlier in life for chronic disease prevention.
- - Future Research: Outline next steps for validating these findings and applying the model to other latent viruses like EBV.
12:15 pm – 1:00pm – Panel: Early Intervention, Big Impact: Regulatory Perspectives on EBV Vaccine Development
- Defining endpoints beyond mono, including surrogate markers for long-term EBV-related diseases.
- Evaluating mono as both a clinical endpoint and surrogate for conditions like MS and IBD.
- Age-targeting strategies: pediatric vs. adolescent populations.
- Balancing early intervention with unknown long-term immune effects.
- Assessing durability of protection and booster needs during peak transmission years.
- Harmonizing data requirements across EBV vaccine developers.
- Fostering collaboration to accelerate development and regulatory alignment.
Unconventional Vaccines Workshop - 3H Bio (AM)
This workshop explores the cutting edge of vaccinology, moving beyond infectious diseases to tackle the world’s most pressing chronic and metabolic conditions. Hosted by 3H Bio, the session brings together global pioneers to discuss how targeted immunological interventions can arrest the progression of atherosclerosis, Alzheimer’s, and obesity.
Attendees will gain insights into:
- Clinical breakthroughs in Tau-targeting vaccines for neurodegeneration.
- Novel platforms like mimotope vaccines for metabolic regulation.
- Translational challenges of moving unconventional vaccines from immunological theory to human clinical trials.
Join us to discover how the next generation of vaccines is being engineered to treat non-communicable diseases and reshape the future of preventative medicine.
11.30am Chair’s opening remarks
11:30 Atherosclerosis Vaccination: From Immunological Concepts to Clinical Translation
11:50 Clinical updates for MultiTEP platform technology-based Tau vaccine for Alzheimer’s
12:10 3HOTP – A mimotope vaccine with anti-obesity and broader metabolic benefits
12:30 Closing Panel Discussion – Common themes and challenges in unconventional vaccine development
Vaccine Delivery Workshop
Advanced vaccine delivery methods: novel routes and technologies to optimize administration, efficacy, and accessibility.
- 2pm Chair’s Opening Remarks: Vaccine Delivery Landscape Overview
- 2:15pm -4:00pm Vaccine delivery presentations:
- 2:15 Enabling mRNA stability and efficacy through innovative lipid nanoparticle components
- 2:30 Improving vaccine uptake and immunization speed with jet injection technology* Title TBC
- Senior Representative, Pharmajet
- 2:45 Needle-Free Frontiers: Practical Considerations for Sublingual and Mucosal Vaccine Delivery Platforms *Title TBC
- Senior Representative, Jurata Thin Film
- 3:00 Senior Representative, Kindeva
- 3:15 Application of Next Gen Tools Including Alternative Delivery Systems and AI To Vaccine and Adjuvant Development
- 3:30 Reserved
- 3:45 Reserved
- 4:00 Panel: Targeting Mucosal Surfaces in Respiratory Vaccine Development
- Inducing mucosal IgA and T cell immunity
- Formulation challenges for nasal and inhaled delivery
- Applicability to flu, RSV, TB and COVID vaccines
- Prospects for mucosal combo vaccines.
GLOBAL HEALTH WORKSHOP (PM)
- entifying innovative and collaborative solutions throughout the development pathway to advance Global Health vaccine candidates beyond historical roadblocks. Understanding the factors which influence access and equity in low resource settings.
- The Global Crisis: Addressing the critical need for next-generation malaria vaccines due to increasing cases and the limitations of current solutions.
- Breakthrough Data: Unveiling the "dream come true" results showing 96% protection against clinical malaria in infants born to mothers vaccinated pre-conception.
- Maternal Immunity: Examining the implications of long-lasting, transferred maternal immunity as a game-changer for infant survival.
- Policy and Elimination: Discussion on how this high, durable efficacy impacts global health policy, funding, scalability, and the path to malaria elimination.Dr Stephen Hoffman, Chief Executive and Scientific Officer, SanariaAdditional Speakers TBC
3:45pm -4:45pm Panel: How Vaccine Access Differs Across Countries—and What to Do About It
- Examine how systems shape vaccine access from development to delivery.
- Contrast vaccine pathways in high- vs. low- and middle-income countries.
- Highlight barriers like trial investment gaps and delayed approvals.
- Share strategies from global experts to improve equitable access.Moderator: Anna Larson, Advisor, Epstein Becker & GreenRebecca Martin, President, Global Immunization, Sabin Vaccine Institute *TBC
5pm -End of Workshop
11am Chair’s opening remarks & presentation:Vaccine Equity—A Historical Perspective and Future ImperativesDr Seth Berkley, Senior Advisor, Pandemic Center at Brown University
11:20am Using a partnership model for peer-to-peer learning and planning to optimize vaccine impact: A case study from Hexavalent Vaccine Implementation in AfricaDr Kate Hopkins, Senior Director of Research, Vaccine Acceptance & Delivery, Sabin Vaccine Institute
11:40am Maternal Immunization Readiness Assessment in Kenya: A Situational Analysis for RSV and GBS Vaccine IntroductionJulie Nyanchama, Kenya Medical Research Institute (KEMRI)
12:00pm Democratizing Adjuvants: An Open-Access Model for Global Health EquityDr Gerben Marsman, Head of Alliance Management, Vaccine Formulation Institute * Speaker TBC
12:20pm Making Vaccine Adjuvant Innovation Accessible to Global HealthReserved, SPI Pharma
12:40pm Presentation TBC
1-2pm Networking Break
GH Vaccine Development Updates:
2:00pm Vaccine Development Updates for Schistosomiasis & Chagas DiseaseDr Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
2:20pm Early development of a blood-stage, whole parasite vaccine for malariaDr Michael Good, Principal Research Leader, Head, Laboratory of Vaccines for the Developing World, Griffith University
2:40pm New Tuberculosis Vaccines *Title TBCProf Richard White, Prof of Infectious Disease Epidemiology, LSHTM; Co-chair, Collaboration for TB Vaccine Discovery EMTD Research Community; WHO TB Vaccine Technical Advisory Group
3:00pm Fireside chat: The 96% Solution: Transforming the Fight Against Malaria Through Unprecedented Maternal and Infant Protection
Create your personal agenda –check the favourite icon
Opening US Government Leadership Keynote Address & Fireside Chat
· Federal agencies view and strategy for the future of public health, infectious disease research and pandemic preparedness in the USA
· Understanding the US government’s vision for regulatory reform
Keynote panel: Navigating the Crowded Respiratory Disease Season, How Are We tackling Flu, COVID, RSV, hMPV?
· How has the respiratory season evolved? Co-circulation of respiratory pathogens, duration of the respiratory disease season, what are the dominant pathogens?
· Where are we seeing innovation in vaccines for respiratory diseases?
· How are we progressing with prophylactic antibodies, combination & universal respiratory vaccine approaches?
· Uptake for Flu, RSV, COVID vaccines. Are we seeing vaccine fatigue from a crowded schedule?
· Globally evolving regulatory and policy landscape
Keynote Address Presentation: Reimagining Global Health Governance: A Finite Mandate Approach for 2035
From Geneva to the Globe: Transitioning Global Health Leadership to Regional and National Actors
· What does a “sunsetting” model look like in practice?
· How can donors be aligned around joint replenishment and reform?
· What are the risks and opportunities of decentralizing global health governance?
· How can regional institutions be empowered and resourced effectively
Keynote Panel: New Developments in Long-Standing Global Health Challenges Disease. A focus on TB, MALARIA & other NTDs
· Tuberculosis:
o TB - Vaccine pipeline: Progress toward 2029–2030 implementation; regulatory and pre-marketing timelines.
o Implementation readiness: Infrastructure, access, early planning and potential health and economic impact in LMICs.
o Global TB strategy: Stakeholders role in shaping global TB policy and strategy, especially in LMICs.
o High-level framing: Positioning TB as a global health security issue
· Malaria:
o Vaccine deployment: Lessons from RTS,S and R21 rollouts.
o Vector control: Innovations to address insecticide resistance.
o Climate impact: Adapting to changing transmission zones.
o Sustained funding: Ensuring long-term support for endemic disease control.
Networking Break
1:10 – 2:30 1-2-1 Partnering
1:30 – 2:20 Start-up pitches
2:00 – 2:30 Poster Presentations
Keynote Address: Evidence Endures: Independent Leadership for Vaccine Policy
Keynote panel - Stronger Together: Vaccine Industry Leadership Vision for Next-Gen Vaccines & Global Collaboration
· 2026 key disease focus areas for vaccine manufacturers, upcoming approvals 2026
· What next generation vaccine platforms have the most impact/potential – why?
· Strengthening public-private collaborations – new partnership opportunities of interest
Keynote Address: AI and the Global South: Opportunities and Guardrails in Vaccine Innovation
Keynote Panel: Resilient, Sustainable, and Decentralized: The Future of Global Vaccine Manufacturing
· Sustainability in Manufacturing
o How are manufacturers integrating green technologies? What are the trade-offs between sustainability and cost in LMICs?
· Regulatory Harmonization & Tech Transfer
o What frameworks are needed to streamline cross-border approvals? How can WHO, AVAREF, and regional blocs support harmonization?
· Decentralized & Modular Manufacturing
o What are the benefits and limitations of mobile/modular units? How can these models be deployed in outbreak-prone or remote regions?
· How are different regions evolving?
Keynote closing panel: Future-Proofing Health – Vaccines Against Climate Threats, Food Insecurity, and AMR
- How can vaccination contribute to our broader global health and sustainability agendas?
- Rethinking our approach from response to prevention: mitigating the effects of climate change and reduction of AMR through vaccination
- The effect of climate change and emerging pathogens on food security, is safeguarding livestock and agricultural productivity shaping vaccine prioritization and funding decisions?
Senior Leadership Representative, WOAH (Dr Emmanuelle Soubeyran, Director/ Dr Montserrat Arroyo Kuribreña Deputy Director, WOAH)
Senior Representative, GSK *TBC
Derrick Sim, Managing Director of Vaccine Markets & Health Security, Gavi *TBC
Dr Rino Rappuoli, Scientific Director, Fondazione Biotecnopolo di Siena; Coordinator, European Vaccine Hub* TBC
Create your personal agenda –check the favourite icon
Chair’s opening remarks
Chair’s Opening Remarks
Chair’s Opening Remarks
Chair’s Opening Remarks
Chair’s opening remarks
Chair’s Opening Remarks
Chair’s opening remarks
Fireside chat: Vaccine Law in Crisis: Safeguarding Public Health Amid Regulatory Rollbacks and Legal Challenges
Panel: Unlocking the Dual Use of Pandemic Platforms
- Designing platforms with dual use in mind
- Scaling up pandemic platforms – what are the remaining bottlenecks?
- How can ‘pandemic platforms’ be adapted to combat high burden or neglected diseases?
- Enabling manufacturing in LMICs to respond to outbreaks and strengthen routine immunization
High-Resolution Antibody Profiling: Using Next-Generation SPR to Guide and Refine Malaria Vaccine Antigen Design
Panel: CD8 T Cells Without Vectors: The Future of Cytotoxic Immunity
- Explore how emerging platforms (e.g. saRNA, DNA, nanoparticles) can induce CD8+ T cell responses without viral vectors.
- Discuss why CD8+ T cells are critical for vaccines targeting cancer, HIV, and chronic infections.
- Importance of antigen processing via proteasome for CD8 activation.
- Examine the immunological signals and delivery strategies needed to drive durable cytotoxic responses.
- Debate the future of CD8-focused vaccine design in a post-vector era.
- Challenges with RNA-based vaccines (e.g., slippage, inflammation).
- Debate on neoantigen selection, vaccine formulation, and delivery vectors.
Biothreats Emergence, Analysis and Communications Network (BEACON) – An Improved Alert System For Emerging Infectious Diseases
Strategies for Improved Access to Trials * Title TBC
Senior Representative, EmVenio
Panel: Title TBC
Senior representative, Cytiva
Panel: One Health Strategies for Smarter Disease Prevention and Control
- Where can improved coordination between animal and human health sectors accelerate vaccine development and delivery?- In what ways can cross-sector collaboration unlock better use of existing tools — vaccines, diagnostics, digital platforms, and cold chain infrastructure?- How do we fund prevention when benefits are shared, but budgets and responsibilities remain siloed?
Panel: Operation Warp Speed: Lessons in Safety from a Pandemic Response
- li>
- Harmonized protocols, central DSMBs, overlapping trial phases.
- Safety monitoring innovations during COVID vaccine development.
- Countering misinformation about rushed development
The Future of US Non -clinical Vaccine Delivery: Lessons from Global Vaccine Distribution and Administration
- li>
- Bridging procurement and regulatory frameworks.
- WHO’s role in harmonization and technical support.
- Innovative models for funding vaccine production, distribution, and delivery.
- Role of multilateral donors, development banks, and public-private partnerships
Longitudinal Immuno-Profiling Studies: 5-Year Cohort Study Covering COVID, Pertussis, Influenza, Herpes
Pandemic Flu Vaccine Development
Vaccine Development Updates for Chikungunya – phase IV and RWE studies *Title TBC
Operationalizing Therapeutic Vaccine Trials for Enhanced Patient Outcomes* Title TBC
Senior Representative, Thermo Fisher Scientific
Panel: Chikungunya & Mosquito-Borne Vaccines: Bridging Outbreak Response, Manufacturing, and Market Creation
- li>
- Outbreak Trends: Chikungunya and mosquito-borne disease surveillance in East Africa and South Asia.
- Vaccine Development: Manufacturing, licensing, and safety insights from CEPI-funded initiatives.
- Policy Challenges: Regulatory hurdles and off-label use in outbreak response settings.
- Market Creation: Strategies for demand generation, stockpiling, and Gavi inclusion.
Vaccine related bills and legislation landscape updates *TBC
GS-LEARN - CEPI's Modelling Initiative in the Global South for Pandemic and Epidemic Preparedness
Panel - State-Level Responses to Shifting Federal Vaccine Guidance
Building Global Readiness: Infrastructure and Capacity for Pandemic Trials* Title TBC
Precision Vaccine Program Research Updates*Title TBC
LNPs for cancer vaccines* Title TBC
Universal Flu Vaccines
The Single-Dose, Highly Attenuated Vaccine for MPOX (TNX-801)* Topic TBC
Preclinical Services - From In Vivo Animal Studies To In Vitro Assay Development and Testing * Title TBC
Senior Representative, IQVIA laboratories
Safety Considerations for Vaccine Trials *Title TBC
Cancer vaccine delivery technology* Title TBC
Senior Representative, Terumo, Europe
Strengthening CEPI’s Mpox Correlates of Protection (Cop) Framework
Navigating Vaccine Trials in Low- and Middle-Income Countries: Challenges and Opportunities*Title TBC
Senior Representative, Syneos Health
Launching & Leading Successful Vaccine Studies: The Essential Role of Parexel’s Site Alliance Network
Senior Representative, Parexel
The Role of Host-Cell DNA Analytics in Optimizing Your Bioprocess Performance
Senior Representative,IDT Biologika
Accelerator™ Drug Development *Title TBC
Senior Representative, Thermo Fisher Scientific
Estimating Background Rates in LMICs: A Hybrid Surveillance Approach to Vaccine Safety & CEPI'S GS-LEARN approach for 100days mission
Vaccine Supply and Demand in Latin America & the Caribbean: Insights from IFC’s Regional Study
The Ripple Effect: Understanding ACIP's Decisions and Their Impact on US Immunization Policy and Access
- li>
- What are the impacts of changes at the ACIP?
- Guaranteeing coverage
- Changes to childhood vaccine schedule
- What does it mean for pharmacists
- What does it mean for patient access?
The Ripple Effect: Understanding ACIP's Decisions and Their Impact on US Immunization Policy and Access
- li>
- What are the impacts of changes at the ACIP?
- Guaranteeing coverage
- Changes to childhood vaccine schedule
- What does it mean for pharmacists
- What does it mean for patient access?
Development of Delivery Systems to Improve Immunotherapy Effectiveness* Title TBC
Accelerating Respiratory Vaccine Trials with Regulatory-Compliant Immunogenicity Testing *Title TBC
Senior Representative, VisMederi
H5N1 Vaccines for Cattle, New Vaccines
Are We Ready Yet? The R&D Innovation Gaps That Still Need Filling *Title TBC
Senior Representative, ATI
Next-Generation MVA Mpox Vaccines: Harnessing an Immunomodulatory Peptide for Single-Dose Efficacy
Optimizing Cell Culture Performance and Consistency with High-Purity Recombinant Proteins
Senior Representative, Novo Nordisk Pharmatech
Assay Development Advances in hMPV and PIV-3 Vaccine Research*Title TBC
Navigating Challenges in Vaccine Trials for Special Populations* Title TBC
Senior Representative, ICON Plc
Enabling Pharma 4.0 Through an Ecosystem Approach to Vaccine Manufacturing
Senior Representative, ReciBioPharm
Panel: Addressing Innovation and Jumpstarting New Projects - The Value & Impact of Product Development Partnerships
- li>
- Enhancing the PDP Model for Global Access: How can product development partnerships (PDPs) be optimized for sustained vaccine affordability and accessibility in LMICs?
- Bridging the R&D Valley of Death: What specific strategies can accelerate the translation of basic research discoveries into viable clinical-stage vaccine projects?
- Strengthening Local Biomanufacturing: How can international collaborations effectively transfer technology and build sustainable vaccine manufacturing capacity in LMICs?
- Evidence-to-Policy Implementation: What mechanisms are needed for rapid integration of vaccine R&D data and evidence into national and global health policy decisions?
- Sustainable Financing for Neglected Diseases: How can diverse funding streams (public, private, philanthropic) be secured to de-risk high-priority, non-commercial vaccine innovation?
The Value of Observational Data Informing Post Licensure Surveillance – How Does It Contribute to Regulatory Decision Making? * Title TBC
Panel: Rethinking Vaccine Supply Chains to Build Sustainable, Locally-Led Immunization Systems
- Building and adapting to increased regional and domestic immunization systems - How are we transitioning vaccine supply and logistics operations for an expanded portfolio and life course vaccination?- Integration of vaccines into medical supply chains- Strategic partnering and sustainable funding approaches to support national immunization strategies and countries graduating from GAVI support.
The Emergence of RNA Vaccines in Animal Health: Use Cases
Senior Representative, Quantoom Biosciences
Understanding the Growing Divide Between Childhood and Adult Vaccination
- li>
- Pediatric vaccination is more vulnerable than adult vaccination in the current climate.
- Panel will examine parental choices, provider trust, and policy support.
- Adult vaccination benefits from mandates, pharmacy access, and clinical backing.
- How are federal policies affecting the Vaccines for Children Program?
- What would state Medicaid programs need to do to replace the VFC program?
- How would those changes affect health equity?
- Goal: identify cross-cutting strategies to strengthen vaccination across all ages.
Next-Level Vaccines: Ionizable Lipids as the Cornerstone of Scalable Success *Title TBC
Senior Representative, Cytiva
Characterization of Vaccine Induced Immune Responses * Title TBC
Targeting mKRAS with ELI-002 Cancer Vaccine – clinical updates *Title TBC
JYNNEOS: An Overview of Clinical Experience and Real World Use
Senior Representative, Bavarian Nordic
Advancing Epidemiological Insights to Drive Clinical Development *Title TBC
Senior Representative, P95
Driving Vaccine Adjuvants and Delivery Systems Development to Secure a Sustainable Supply*Title TBC
From Awareness to Action: Transforming Trial Enrollment * Title TBC
Senior Representative, AMR
Breaking New Ground: NTx’s Advances in Biopharmaceutical Technology and Future Horizons*Title TBC
Senior Representative, NTx
Catalyzing Change: How Investment in the Livestock Sector Drives Pandemic Prevention and One Health Outcomes
Strategies for Large Scale Vaccinations for the World – Multidose Vial and CMC Challenges
Successfully Advancing Vaccines for Pre-Clinical Development * Title TBC
Senior Representative, Thermo Fisher Scientific
US/EU First in human study targeting dark genome-derived neoantigens
Raising the Temperature: New Challenge Agents, Febrile Illness, and Vaccine Efficacy Testing
Senior Representative, hVIVO
Panel: The Advantages of Running Vaccine Clinical Trials in Australia *Title TBC
Two Case Studies of Vaccine Development using Simple Western™ Technology: V590 COVID Vaccine HCP Content and V937 Coxsackievirus Vaccine Full and Empty Particle Analysis
Senior Representative, Merck
Panel: Public-Private Partnerships for Pandemic Readiness & Biosecurity: Models That Work
- li>
- Frameworks and pre-agreements for rapid mobilization of public and private resources
- Case studies of successful PPPs (e.g., COVID-19 vaccine partnerships)
- Aligning incentives and access obligations across sectors and funders
- Evolving global funding roles and the impact of the Pandemic Accord
- Building resilient partnerships to ensure equitable innovation and deployment
Revisiting Thimerosal – A Case Study in Vaccine Safety and Public Perception
- li>
- Re-examine the scientific evidence surrounding thimerosal and neurodevelopmental outcomes.
- Explore how misinformation and politicization shaped public perception and policy decisions.
- Reflect on the implications of recent ACIP actions and the normalization of anti-science rhetoric.
- Discuss the global relevance of thimerosal, especially in LMICs where multi-dose vials are still used.
Panel: Vaccines and Value: Navigating Care, Cost, and Controversy in a Shifting Policy Landscape
- li>
- Why vaccines are essential to value-based, person-centered, prevention-focused care
- The importance of vaccine insurance coverage and potential impact of ACIP changes
- Vaccine cost-effectiveness and the impact of pricing
- Physicians’ strategies for addressing vaccine hesitancy
- The intersection of public health and health system sustainability
Next generation tissue selective lipid and polymer-based Selectivity Enabling Nano Shell (SENSTM) technology optimized for prophylactic and therapeutic applications
Senior Representative, Samyang Holdings Corp. Biopharm Group
Leveraging CRISPR-Cas9 for a Next-Generation Malaria Vaccine* Title TBC
Next Generation Pandemic Vaccine Development *Title TBC
Defining Correlates of Protection for ID *Title TBC
Synergizing Modalities: Clinical Progress Across an Integrated Oncology Portfolio
Senior Representative, Biontech *TBC
Standardizing the viral quality control lifecycle for next-generation respiratory vaccines *Title TBC
Senior Representative, Microbiologics
Title TBC
Senior Representative, SSI Diagnostica
A Standout Advantage: High quality results delivered with speed and scale
Enabling Combination Adjuvants Via Synthetic Biology
Development of a Trivalent Cell-Culture-Based Vaccine Against Foot-and-Mouth Disease
Chikungunya Vaccine Safety: Lessons from Post-Licensure Surveillance and Regulatory Pathways
- li>
- Examine post-licensure safety signals and regulatory response following serious adverse events in elderly recipients.
- Explore the expedited approval pathway and implications of limited trial data, especially in high-risk populations.
- Compare live attenuated vs. VLP platforms in terms of safety and suitability for outbreak response.
- Discuss global equity challenges in vaccine deployment and risk tolerance in LMICs
Adjuvant heat stability and the future of vaccine cold chain independence *Title TBC
Senior Representative, Chongqing BDSyn Biotechnology Co., Ltd
Utilizing RPV Vectors to Elicit Durable T-Cell Responses against Re-Emerging Viral Families *Topic TBC
From Variant Detection to First Patient Dosed in days: How Technology and Changing Regulations are Rewriting the Vaccine Trial Playbook
Senior Representative, Flourish Research
Transforming Vaccine Development and Manufacturing: Integrating Technology and Accessibility for a Healthier 21st Century*Title TBC
Senior Representative, WuXi Vaccines
Panel: Old Foes – New Vaccines: Innovation in Veterinary Vaccines
- New approaches to longstanding diseases: African swine fever, Avian influenza.- Improving our understanding recombination, immunology and vaccine targets.- How do we define and measure "impact" in the absence of sterile immunity – DIVA vaccines?- Innovative delivery systems including microneedle patches, intranasal, and oral platforms for mass vaccination- Multivalent vaccine development: navigating formulation, stability, and immune interference across species
Needle-Free, Not Market-Free: Unlocking the Commercial Potential of Next-Gen Vaccine Delivery
- li>
- Scaling Innovation: Expanding novel delivery formats in LMICs needs strong public-private partnerships and tech transfer.
- System Readiness: Promising technologies face adoption barriers due to limited infrastructure and regulation (PPP and tech-transfer). Are health systems and delivery programs equipped for novel formats?
- Formulation Focus: Adjuvants and formulation science are key to effective, scalable needle-free platforms.
- Strategic Coordination: Aligning science, strategy, and scale-up is vital to move innovations into practice.
Self-Amplifying mRNA: Opportunities for Development of Vaccines Against Complex Biological Targets
Modulating Immunity: Updates on Checkpoint, KRAS, and Individualized Neoantigen Therapies
Maximizing Vaccine Trial Efficiency with eSource Technology * Title TBC
Senior Representative, CRIO
Removing the Freezer: Thermostable Platforms as the Essential Step for Next-Generation Vaccine Access*Title TBC
Senior Representative, Jurata Thin Film
Strength in Collaboration: Surveillance and Safety for Marburg Vaccine Trials
Senior Representative, Sabin Vaccine Institute *TBC
A Versatile Vaccine Manufacturing Platform for Pandemic Preparedness: From COVID-19 to Influenza
Novel Method: Uses riboflavin and UV light to inactivate viruses without damaging proteins—avoids harsh chemicals.
COVID-19 Vaccine: SolaVAX™ CoV-2 showed strong, lasting immunity and variant coverage in pre-clinical studies.
Flu Vaccine: SolaVAX-Flu-Q induced high antibody responses in mice against four seasonal strains.
Platform Potential: Enables rapid, broad-spectrum vaccine development for emerging threats.
Driving Trial Performance with Real-World Insights and Advanced Analytics
Cleaning Validation Strategies and Challenges for Vaccines
Senior Representative, Simtra Biopharma Solutions
Protective Pan-Betacoronavirus Neutralizing Antibodies by Vaccination
SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade
Development Of 24-Valent Pneumococcal Conjugate Vaccine
AI-Powered Target Discovery for Infectious Disease Vaccines*Title TBC
Accelerating Vaccine Clinical Trials: The Power of Pratia's Decentralized and Comprehensive Site Network *Title TBC
Senior Representative, Pratia
Sustainable Vaccine Manufacturing*Title TBC
Senior Representative, Cytiva
New Approaches to Antigen Identification, Immunogenetics, Host-Pathogen Interactions
Ebola Surveillance: Navigating Safety in Crisis Zones
- li>
- Safety monitoring during trials in politically unstable regions (e.g., Congo, Uganda).
- Comparison of Merck and J&J approaches
- Post-licensure surveillance in outbreak settings
Addressing Declining Immunization Rates Through Digital Accessibility *Title TBC
Understanding vaccine markets
Reserved, McKinsey
A Novel Lipopeptide Platform for Pan-Coronavirus Vaccine Development
Human Trial of New Nipah Vaccine Bangladesh
Panel: One Health, One Standard: Driving Global Regulatory Convergence
- Moving vaccines to market faster in emergency situations- Global regulatory harmonization – aligning with Europe and global markets- Understanding processes for innovative technologies
FDA Pre-Check Program: An Industry Perspective on Localising Manufacturing and Maintaining Quality *Title TBC
Addressing declining immunization rates through digital accessibility *Title TBC
A Global Roadmap for Durable, Broadly Protective, and Next-Generation Coronavirus Vaccines
Defining Immunobridging: Nuances, Regulatory Precedent, and Use Cases for Accelerated Vaccine Access
Panel: From Biomarkers to Vaccines: Diagnostic Innovation in Cancer Immunotherapy
- Navigating regulatory pathways for diagnostics in immunotherapy and cancer vaccine development.
- Ensuring diagnostic tool rigor across diverse technologies—wearables, imaging, software, and lab-based platforms.
- Bridging oncology and vaccine diagnostics: harmonizing standards across therapeutic areas.
- The evolving role of companion diagnostics in enabling personalized immunotherapies.
- Holistic integration of precision medicine tools into clinical development from a regulatory perspective.
Innovating in Respiratory Vaccines: Analytical Insights into Pneumococcal Candidate Development
Panel: Climate Change and the Shifting Landscape of Infectious Diseases*Topic Title TBC
- How is climate change affecting disease distribution and frequency?- What areas are at risk from emergence and re-emergence?- How can climate change data be integrated with disease surveillance and how is this informing planning and procurement for vaccination programs?- Reviewing the pipeline for vaccines against mosquito borne diseases – where are our priorities for vaccine R&D?- How do we predict the effect of climate change on vaccine distribution e.g. cold chain capabilities?
mRNA Synthesis with Improved RNA Polymerases: Prima RNApolstm For High Quality, Streamlined And Cost-Effective mRNA Manufacturing*Title TBC
Senior Representative, Primrose Bio
Panel: Platforms Are Out, Products Are In: What VCs & Private Investors Really Want
- is panel will explore the shifting priorities in venture capital investment within the vaccine and biotech space. Historically, platforms promised broad, long-term innovation, but today’s market increasingly favors tangible, indication-specific products. Is this a cyclical trend or a fundamental shift? Join leading VCs as they debate the future of biotech funding, the role of hype, and what startups must do to attract investment in a more cautious, product-driven landscape.
- Understand the current VC investment climate in biotech and vaccines.
- Explore the tension between platform-based innovation and product-focused funding.
- Discuss how hype and market cycles influence valuations and investor interest.
- Provide actionable insights for startups seeking VC attention.
Panel: Title: Vaccine Safety in the Absence of Consensus – Surveillance, Standards, and the Future of Public Health
- th the traditional vaccine policy infrastructure in flux—most notably the disruption of the ACIP and diverging guidance from federal agencies—this panel will explore how the landscape of vaccine safety is being reshaped. Who now sets the standard for vaccine recommendations? How are safety and efficacy being monitored without centralized oversight? And what are the long-term implications for public trust and public health?This session will bring together leaders from professional societies, state-level epidemiology, and academic institutions to discuss:
- The evolving role of organizations like CSTE, AAP, ACOG, and CIDRAP in filling the policy vacuum.
- Innovative approaches to vaccine safety surveillance in a decentralized environment.
- The historical role of the ACIP and what its disruption means for the future.
- Strategies for maintaining scientific integrity and public confidence in a fragmented system.
- State vs local level
Manufacturing for Domestic Health Security: Goals, Incentives, Strategic Partnerships
- li>
- ASPR-led update on centralizing domestic vaccine/API manufacturing
- Strategic goals and public-private incentives
- Emergency response challenges and solutions
The Crucial Role of Tone: Sustaining High Vaccine Uptake Through Effective Public Health Messaging
- li>
- Public health messaging tone is crucial, even in pro-vaccine areas.
- Focus on proactive misinformation prevention and effective message framing.
- Emphasizes maintaining strong community partnerships.
- Shares best practices from high-uptake areas to inform low-uptake strategies
Panel: Broadly Protective Vaccines – Where Are We?
- Continuing R&D against coronaviruses: has ‘COVID fatigue’ also stalled research and investment? - Target product profile: who, what and when?- Do we understand enough about circulating coronaviruses & other respiratory viruses like influenza to have sufficient coverage against high risk variants?- Stimulating mucosal immunity in non-naive populations and improving our understanding of correlates of protection.- Economic perspectives on funding BP vaccines – funding mechanisms, market dynamics
Panel: Immunobridging for Accelerated Vaccine Access: From Preclinical Models to Real-World Application
· Defining Immunobridging– Use cases in outbreak scenarios and population expansion.
· Assay Development & Standardization– Challenges in T-cell vs. antibody assays
· Data Integration & AI Tools– Improving comparability and accessibility.
· Case Studies– MPOX, Nipah, MERS, Chikungunya.
· Academic vs. Operational Perspectives– Translating research into scalable solutions.
Panel: Human Challenge Models: A New Gold Standard?
- li>
- Evaluate HCMs as faster, cost-effective alternatives to Phase III trials, especially for outbreak-prone diseases.
- Share real-world examples from CEPI’s CHIM consortium and other global initiatives.
- Discuss regulatory and ethical frameworks for participant safety and trial approval.
- Explore operational challenges including infrastructure, biosafety, and assay standardization.
- Examine the role of immunobridging in translating animal data to human efficacy.
- Debate future potential of HCMs in mainstream vaccine licensure, including AI and biomarker integration.
Panel: Translating Public R&D Into Animal Health Innovation
- What makes a publicly developed animal health technology attractive to industry?- How do governments decide when to advance a vaccine candidate, and when to hand it off?- Are there good models for co-development or joint IP stewardship in animal health?- What lessons can we draw from human health partnerships (e.g. CEPI, HERA) for veterinary tech transfer?- How do we avoid duplicating efforts across countries — is there scope for shared platforms?
Securing the Supply Chain: ATI's BioMaP-Consortium for Resilient Biopharmaceutical Manufacturing* TBC
Senior Representative, ATI
Rapid, Precise, And Scalable Characterization of Plasmid Isoforms to Ensure Critical Quality Attributes In Vaccine Production
Senior Representative, Agilent
Create your personal agenda –check the favourite icon
COVID-Flu Combination Vaccine Development Updates
Panel: Designing Clinical Trials for Emerging Threats
Manufacturing next-generation vaccines: Scaling up outer membrane vesicle production to GMP standards
Strategies for the Reduction of Agricultural Methane Emissions
- li>
- Challenges in targeting methanogenic microbes across diverse gut ecosystems, as well as achieving high rates of methane-reduction efficiency
- Regulatory and practical challenges of deploying methane reducing vaccine
- Possible applications of methane-reducing technology to other organisms and greenhouse gases
Fireside chat: Can AI Be Trusted with the Truth? Health Messaging in a Misinformation Age
Combining Respiratory Vaccines: COVID And Flu
Title TBC
Senior Representative, SSI Diagnostica
Immunological Imprinting and Dose Timing: Data-Driven Considerations for COVID-19 Strain Selection
Ex vivo model of functioning human lymph node reveals role for innate lymphocytes and stroma in response to vaccine adjuvant
Empowering the Frontline: How Nurse-Led Innovation Builds Vaccine Confidence and Safer Delivery Models
Mapping the Burden of Respiratory Viruses to Support Next-Gen Combination Vaccine Programs * Title TBC
AI-Powered Target Discovery for a Novel CMV Vaccine
Panel: Strain Selection for Respiratory Vaccines: Aligning Science, Strategy & Schedules
- li>
- Timing tensions between flu (Feb–Mar) and COVID (May–Jun) strain selection.
- Understanding the epidemiology and selective pressures on respiratory viruses informing strain selection times
- Platform disparities in speed to market (mRNA vs. protein vs. egg-based).
- Scientific debate over lineage-level vs. strain-level selection strategies.
- Impact of combo vaccines on aligning strain selection schedules.
- Variant unpredictability challenges the value of late-season selections
Panel: Genetic Adjuvants & mRNA Vaccine Durability: Next-Gen Strategies for Enhanced Immune Response
Introduction & Context:o Challenges with mRNA vaccine durability and breadtho Emerging role of genetic adjuvantso Relevance to pandemic preparedness and immunological innovationTalk 1: Mechanisms & Promise of Genetic Adjuvantso Overview of cytokine-encoded mRNA adjuvantso IL-12 and other promising candidateso Immunological mechanisms and delivery challengesTalk 2: Enhancing mRNA Vaccine Breadth & Durabilityo Case studies on combining mRNA vaccines with genetic adjuvantso Data on durability, breadth, and safetyo NIH funding landscape and regulatory considerationsTalk 3: Translational & Clinical Perspectiveso Preclinical and early clinical datao Formulation and delivery innovationso Potential applications beyond infectious disease (e.g. allergy, autoimmunity)Discussion & Audience Q&Ao Where do genetic adjuvants fit in the current vaccine tech landscape?o Regulatory hurdles and funding gapso Opportunities for collaboration and future research
Panel: Combining Respiratory Vaccines - Balancing Efficacy, Durability and Immunization Schedules
- What should we combine? Bi and Tri Pathogen vaccines.- What do we understand about efficacy, immunology and durability of combinations?- Balancing are we considering seasonality across diverse geographies?- Regulatory and policy considerations.
Panel: How Close Are We to Licensure of A CMV Vaccine? Lessons For Latent Virus Control
- What immunological and technical barriers remain in targeting CMV, and why has progress been so slow?- How are different platforms—mRNA, VLP, subunit, viral vectors—addressing the challenges of antigen complexity and needs of diverse patient groups?- How might progress in CMV vaccine R&D inform broader strategies for tackling other persistent viral infections?
Panel: Venture Philanthropy for Vaccines – A Powerful Engine to Do Good
- li>
- Explore how venture philanthropy bridges public health goals with private capital returns.
- Showcase successful case studies in vaccine development for cancer, T1D, ALS, and more.
- Discuss how these funds de-risk early science and catalyze VC and pharma engagement.
- Highlight the untapped potential in infectious diseases, AMR, and global health.
- Offer insights into future models of funding and collaboration in vaccinology
Vaccine Supply and Demand in Latin America & the Caribbean: Insights from IFC’s Regional Study
Developing Holistic and Mechanistic Potency Assays for Next-Generation Vaccines* Title TBC
Quality Evaluation of mRNA-LNP Vaccines by Innovative Biophysical Methods
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events